Prognostic Factors of Advanced Ovarian Cancer in the Era of HIPEC: A Multicenter Retrospective Study from an ESGO-Certified Center and an ESPSO-Certified Center

<b>Background/Objectives</b>: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) may modify the prognostic impact of established clinical and surgical factors in advanced ovarian cancer. A retrospective study was conducted to identify independent predictors of survival, recurrence patterns and major postoperative complications in the HIPEC setting. <b>Methods</b>: In total, 265 women with advanced-stage ovarian cancer operated on between 2015 and 2019 were included. Patients were treated with CRS, with or without HIPEC. Patients' characteristics, oncological and follow-up information were collected. <b>Results</b>: In total, 62.3% underwent primary CRS, and 39.2% received HIPEC, with complete or near-complete cytoreduction (CC-0/1) achieved in 85.6%. Major complications (≥grade III) were recorded in 16.6% of the patients. HIPEC, high peritoneal cancer index (PCI), and greater intraoperative blood loss were found to independently increase the odds of major postoperative complications, while prior surgery was the only independent predictor of local-regional recurrence. The median follow-up was 34 months, with a median progression-free (PFS) and overall survival (OS) of 26 and 77 months, respectively. Multivariable analysis identified systematic lymphadenectomy and serous histology as independent predictors for PFS and also for OS, with the addition of CC-3. Survival analysis with Kaplan-Meier curves revealed that CRS plus HIPEC was associated with significantly better OS, but not PFS, compared with CRS alone. <b>Conclusions</b>: Systematic lymphadenectomy, serous histology, and absence of macroscopic gross residual disease emerge as key independent favorable prognostic factors in the HIPEC era, while prior surgery adversely affects loco-regional control. CRS plus HIPEC improved OS in this specific regimen's perfusion protocol but was associated with higher major postoperative complications, underscoring the need for careful patient selection.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2026-02-13
DOI
https://doi.org/10.3390/biomedicines14020431
Primary Topic
Intraperitoneal and Appendiceal Malignancies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prognostic Factors of Advanced Ovarian Cancer in the Era of HIPEC: A Multicenter Retrospective Study from an ESGO-Certified Center and an ESPSO-Certified Center

Dimitrios Zouzoulas, A. Kalakonas, Eleni T. Timotheadou, Vasilis Theodoulidis et al.
Biomedicines
Intraperitoneal and Appendiceal Malignancies
article

Prognostic Factors of Advanced Ovarian Cancer in the Era of HIPEC: A Multicenter Retrospective Study from an ESGO-Certified Center and an ESPSO-Certified Center

Dimitrios Zouzoulas, A. Kalakonas, Eleni T. Timotheadou, Vasilis Theodoulidis, Dimitrios Kyziridis, Antonios-Apostolos Tentes
article en

Abstract

<b>Background/Objectives</b>: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) may modify the prognostic impact of established clinical and surgical factors in advanced ovarian cancer. A retrospective study was conducted to identify independent predictors of survival, recurrence patterns and major postoperative complications in the HIPEC setting. <b>Methods</b>: In total, 265 women with advanced-stage ovarian cancer operated on between 2015 and 2019 were included. Patients were treated with CRS, with or without HIPEC. Patients' characteristics, oncological and follow-up information were collected. <b>Results</b>: In total, 62.3% underwent primary CRS, and 39.2% received HIPEC, with complete or near-complete cytoreduction (CC-0/1) achieved in 85.6%. Major complications (≥grade III) were recorded in 16.6% of the patients. HIPEC, high peritoneal cancer index (PCI), and greater intraoperative blood loss were found to independently increase the odds of major postoperative complications, while prior surgery was the only independent predictor of local-regional recurrence. The median follow-up was 34 months, with a median progression-free (PFS) and overall survival (OS) of 26 and 77 months, respectively. Multivariable analysis identified systematic lymphadenectomy and serous histology as independent predictors for PFS and also for OS, with the addition of CC-3. Survival analysis with Kaplan-Meier curves revealed that CRS plus HIPEC was associated with significantly better OS, but not PFS, compared with CRS alone. <b>Conclusions</b>: Systematic lymphadenectomy, serous histology, and absence of macroscopic gross residual disease emerge as key independent favorable prognostic factors in the HIPEC era, while prior surgery adversely affects loco-regional control. CRS plus HIPEC improved OS in this specific regimen's perfusion protocol but was associated with higher major postoperative complications, underscoring the need for careful patient selection.

BiomedicinesVol. 14(2)
Aristotle University of Thessaloniki (GR), Kyanous Stavros Hospital (GR), Papageorgiou General Hospital (GR)
Good health and well-being
Openalex Percentile: Top 58%
Intraperitoneal and Appendiceal Malignancies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.